Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

FEMSA To Enter U.S. Cash & Carry Segment With JRD Stakes

Published 09/26/2019, 09:20 PM
Updated 07/09/2023, 06:31 AM

Fomento Economico Mexicano, S.A.B. de C.V. (NYSE:FMX) , alias FEMSA, signed a non-binding Memorandum of Understanding (MOU) to buy a minority stake in Jetro Restaurant Depot (JRD), a leader in the wholesale business-to-business cash and carry retail foodservice unit in the United States. The company will begin a Joint Venture (JV) with JRD to take JRD’s business model to Mexico and other Latin American markets.

Per the MOU, FEMSA will acquire stakes in JRD for about $750 million. The company anticipates signing a definitive agreement to validate the MOU in the month of October, with the deal likely to close in fourth-quarter 2019. However, the deal remains subject to satisfaction of customary regulatory approvals and conditions.

The deal will mark FEMSA’s entry in the U.S. wholesale cash and carry business segment. It will also provide the necessary background to form a new JV that can aid growth in its core markets.

Over the years, the company has been taking prudent steps to diversify its product portfolio while expanding in the small-box retail segment. Its recent agreement to form a 50-50 JV with Raízen Conveniencias in Brazil, marking FEMSA Comercio’s entry in the country’s convenience sector, clearly justifies its expansion plan. The deal, which enables FEMSA Comercio to buy a 50% stake in Raízen for R$561 million, is likely to close in the second half of 2019.

This follows FEMSA Cadena Comercial OXXO’s (OXXO stores) commercial pact to sell Grupo Modelo’s beer brands, including Corona and Pacifico, signed in February 2019. Notably, OXXO stores exclusively sold beer for Heineken’s (OTC:HEINY) Mexican subsidiary — Cervezas Cuauhtemoc Moctezuma — under the 10-year commercial agreement that dates back to 2010. FEMSA extended the pact with HEINEKEN Mexico for another five years, with some key changes, including provisions for the sale of beer brands from Heineken and Grupo Modelo in Mexico.

Starting from 2019, OXXO stores are simultaneously selling both brand portfolios in Mexico’s biggest cities, including Mexico City and Guadalajara. This will be extended to stores nationwide by 2022. These deals will not only enhance the productivity of the beer category but also add value to the Mexican beer industry. It will also boost the value proposition of OXXO stores, which contributes nearly 35% to FEMSA’s revenues.

Moreover, FEMSA, which shares space with Monster Beverage (NASDAQ:MNST) and PepsiCo (NASDAQ:PEP) , is focused on expanding drugstore operations as it sees significant potential in that space. It is aggressively seeking to capitalize on the growing drugstore industry through the acquisition of Ecuador-based Corporación GPF (“GPF”). Further, FEMSA is on track to build infrastructure and integrate its four legacy drugstore operations into a single operating platform. These include its previously acquired Mexican drugstore business — Farmacias YZA, Farmacias FM Moderna and Farmacias Farmacón — as well as South America’s leading drugstore operator, Grupo Socofar. We believe that the company’s venture into the drugstore business strategically fits its chain-store business and will be accretive to its top line and bottom line in the long term.



Notably, this Zacks Rank #2 (Buy) company has increased 9.6% so far in a year compared with the industry’s growth of 13.2%. Shares of the company have increased around 6% in the past one month.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Heineken NV (HEINY): Free Stock Analysis Report

Fomento Economico Mexicano S.A.B. de C.V. (FMX): Free Stock Analysis Report

Monster Beverage Corporation (MNST): Free Stock Analysis Report

Pepsico, Inc. (PEP): Free Stock Analysis Report

Original post

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.